Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Antisense therapy has generated waves of enthusiasm and disappointment. With a new drug about to be submitted for approval, is it on the cusp of becoming established as a platform technology?
Richard Bergström, the newly appointed Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA), discusses his plans for restoring Europe's drug R&D competitiveness.
Vessel normalization strategies aim to increase tumour perfusion and oxygenation, and have the potential to reduce metastasis and improve responses to conventional anticancer therapies. Here, Carmeliet and Jain discuss the benefits and limitations of this emerging new treatment paradigm for cancer and other angiogenic disorders.
Although investment in pharmaceutical research and development (R&D) has increased substantially in recent decades, the lack of a corresponding increase in the output in terms of new drugs being approved indicates that therapeutic innovation has become more challenging. Here, using a large database that contains information on R&D projects for more than 28,000 compounds investigated since 1990, Riccaboni and colleagues examine the factors underlying the decline in R&D productivity, which include an increasing concentration of R&D investments in areas in which the risk of failure is high.
Treatment of type 1 diabetes by immunotherapy offers a novel strategy to improve clinical outcomes. Here, Waldron-Lynch and Herold discuss the immunopathogenesis of type 1 diabetes, the translation of experimental findings to clinical trials and future therapy.
Here, the authors highlight how inhibiting NOX1 and NOX2 oxidases could be a promising approach for combating oxidative stress. They discuss how a better understanding of the interactions of specific subunits of NADPH oxidases may enable the development of novel isoform-selective drugs to treat vascular diseases.
